Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REM0046127 in mild to moderate Alzheimer's disease
NCT05478031Phase 2Terminated
- Sponsor
- reMYND
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rem0046127 in Alzheimer's disease (AD), sponsored by reMYND. Started Jun 2022; status: terminated.
02
Drugs
rem0046127
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05478031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478031.